Skip to main content
Gary Sachs, MD, Psychiatry, Boston, MA

GaryStevenSachsMD

Psychiatry Boston, MA

Addiction

Associate Clinical Professor of Psychiatry, Massachusetts General Hospital

Dr. Sachs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sachs' full profile

Already have an account?

  • Office

    15 Parkman St
    Wac 8
    Boston, MA 02114
    Phone+1 617-724-6544
    Fax+1 617-726-6768

Education & Training

  • Massachusetts General Hospital/McLean Hospital
    Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1983 - 1986
  • University of Maryland/Sheppard Pratt
    University of Maryland/Sheppard PrattResidency, Psychiatry, 1982 - 1982
  • University of Maryland School of Medicine
    University of Maryland School of MedicineClass of 1982

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1988 - Present
  • MA State Medical License
    MA State Medical License 1984 - 2025
  • FL State Medical License
    FL State Medical License 2019 - 2021
  • MD State Medical License
    MD State Medical License 1983 - 1983
  • American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Antidepressants in Bipolar Disorder: STEP into the Light 
    161st Annual Meeting, Washington, DC, USA
  • Antidepressants in Bipolar Disorder: STEP into the Light 
    American Psychiatric Association, 161st Annual Meeting, Washington, DC, USA

Press Mentions

  • U.S. FDA Approves VRAYLAR® (Cariprazine) as an Adjunctive Treatment for Major Depressive Disorder
    U.S. FDA Approves VRAYLAR® (Cariprazine) as an Adjunctive Treatment for Major Depressive DisorderDecember 17th, 2022
  • Antipsychotic Safe, Effective for Resistant Depression in Phase 3 Trial
    Antipsychotic Safe, Effective for Resistant Depression in Phase 3 TrialMay 26th, 2022
  • Add-on Vraylar Tied to Easing of Recurrent Depressive Symptoms
    Add-on Vraylar Tied to Easing of Recurrent Depressive SymptomsMay 22nd, 2022
  • Join now to see all

Grant Support

  • Pilot Study Of A Calcium Channel Blocker In FemalesNational Institute Of Mental Health1999–2000
  • Treatment Of Bipolar DisorderNational Institute Of Mental Health1998–2000